Publications
Peer-reviewed work, filterable.
Papers from our discovery platform and clinical programs. Filter by year, journal, or program.
8 publications
-
Structure-based design of a once-daily CDK4/6 inhibitor with selectivity over CDK1 and CDK2
The BPC-101 discovery program: crystallography-guided optimization yielding a selective CDK4/6 inhibitor suitable for once-daily oral dosing.
DOI Sample -
Phase 1 dose escalation of BPC-101 in HR+ breast cancer: safety and recommended Phase 2 dose
First-in-human results from the BPC-101 monotherapy and combination expansion cohort in HR+/HER2- metastatic breast cancer.
DOI Sample -
An Fc-engineered anti-CD19 antibody with enhanced antibody-dependent cellular cytotoxicity
Preclinical characterization of BPC-203, an Fc-engineered anti-CD19 monoclonal antibody with selective natural killer cell engagement.
DOI Sample -
Targeted degradation of TYK2 suppresses interferon-alpha signaling in autoimmune models
Discovery and preclinical profiling of BPC-305, a selective TYK2 degrader that silences interferon-alpha receptor signaling.
DOI Sample -
An anti-HER3 antibody-drug conjugate with activity in EGFR-mutant non-small cell lung cancer
Preclinical and early clinical characterization of BPC-402, a HER3-directed antibody-drug conjugate with a topoisomerase I payload.
DOI Sample -
Neutralization of TL1A reduces mucosal inflammation in preclinical colitis models
Mechanism of action and preclinical efficacy of BPC-612, a humanized anti-TL1A antibody for inflammatory bowel disease.
DOI Sample -
A structure-guided platform for the discovery of selective kinase inhibitors
An overview of the structure-guided discovery platform underlying the BPC-101 and BPC-305 programs.
DOI Sample -
Antibody and antibody-drug conjugate discovery using engineered Fc libraries
Description of the Fc engineering library used to discover BPC-203 and to assemble the BPC-402 linker-payload.
DOI Sample